Neurobiology of Disease

Journal

Publication Venue For

  • Effects of exercise on sleep in neurodegenerative disease.  140. 2020
  • A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid-β toxicity.  134. 2020
  • Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions.  134. 2020
  • LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease.  134. 2020
  • Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?.  132. 2019
  • Multigenerational epigenetic inheritance: One step forward, two generations back.  132. 2019
  • Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration.  125:146-153. 2019
  • Human and rodent temporal lobe epilepsy is characterized by changes in O-GlcNAc homeostasis that can be reversed to dampen epileptiform activity.  124:531-543. 2019
  • Pα-syn* mitotoxicity is linked to MAPK activation and involves tau phosphorylation and aggregation at the mitochondria.  124:248-262. 2019
  • Reduction of microglial progranulin does not exacerbate pathology or behavioral deficits in neuronal progranulin-insufficient mice.  124:152-162. 2019
  • TFEB dysregulation as a driver of autophagy dysfunction in neurodegenerative disease: Molecular mechanisms, cellular processes, and emerging therapeutic opportunities..  122:83-93. 2019
  • Corrigendum to “Deficits in synaptic function occur at medial perforant path-dentate granule cell synapses prior to Schaffer collateral-CA1 pyramidal cell synapses in the novel TgF344-Alzheimer's Disease Rat Model” [Neurobiology of Disease Volume 110, February 2018, Pages 166–179] (S0969996117302759) (10.1016/j.nbd.2017.11.014)).  118:177-178. 2018
  • Astrocyte-specific DJ-1 overexpression protects against rotenone-induced neurotoxicity in a rat model of Parkinson's disease.  115:101-114. 2018
  • Behavioral and SCN neurophysiological disruption in the Tg-SwDI mouse model of Alzheimer's disease.  114:194-200. 2018
  • Muscle microRNA signatures as biomarkers of disease progression in amyotrophic lateral sclerosis.  114:85-94. 2018
  • Deficits in synaptic function occur at medial perforant path-dentate granule cell synapses prior to Schaffer collateral-CA1 pyramidal cell synapses in the novel TgF344-Alzheimer's Disease Rat Model.  110:166-179. 2018
  • The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein.  110:68-81. 2018
  • Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease.  109:249-257. 2018
  • Effects of α-synuclein on axonal transport.  105:321-327. 2017
  • α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration.  105:84-98. 2017
  • Dysregulation of BET proteins in levodopa-induced dyskinesia.  102:125-132. 2017
  • Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity.  98:122-136. 2017
  • The neurobiology of HIV and its impact on cognitive reserve: A review of cognitive interventions for an aging population.  92:144-156. 2016
  • An altered peripheral IL6 response in major depressive disorder.  89:46-54. 2016
  • Astrogliopathology in neurological, neurodevelopmental and psychiatric disorders.  85:254-261. 2016
  • Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteins.  79:1-13. 2015
  • Differential proteomic and behavioral effects of long-term voluntary exercise in wild-type and APP-overexpressing transgenics.  78:45-55. 2015
  • Hyperactivity and cortical disinhibition in mice with restricted expression of mutant huntingtin to parvalbumin-positive cells.  62:160-171. 2014
  • Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease.  70:190-203. 2014
  • Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease.  62:113-123. 2014
  • Enhanced Ca2+-dependent glutamate release from astrocytes of the BACHD Huntington's disease mouse model.  58:192-199. 2013
  • RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells.  54:264-279. 2013
  • Neurodevelopmental impairment following neonatal hyperoxia in the mouse.  50:69-75. 2013
  • Preferential inactivation of SCN1A in parvalbumin interneurons increases seizure susceptibility.  49:211-220. 2013
  • Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA.  47:416-427. 2012
  • 8OHdG as a marker for Huntington disease progression.  46:625-634. 2012
  • Saccadic latency in Parkinson's disease correlates with executive function and brain atrophy, but not motor severity.  43:79-85. 2011
  • Update on the pathology of dystonia.  42:148-151. 2011
  • Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and Ataxia.  41:11-22. 2011
  • Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis.  40:531-543. 2010
  • Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader-Willi syndrome.  39:169-180. 2010
  • Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia.  38:434-445. 2010
  • Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention.  37:510-518. 2010
  • VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease.  37:330-338. 2010
  • Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations.  35:219-233. 2009
  • Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease.  34:525-534. 2009
  • Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MECP2 mutations.  34:199-211. 2009
  • Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia.  34:133-145. 2009
  • Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology.  34:163-177. 2009
  • Decreased glutamate transport enhances excitability in a rat model of cortical dysplasia.  32:254-261. 2008
  • Transcriptional dysregulation in a transgenic model of Parkinson disease.  29:515-528. 2008
  • Effects of gender on nigral gene expression and parkinson disease.  26:606-614. 2007
  • Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia.  24:318-325. 2006
  • Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's disease.  24:280-285. 2006
  • Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease.  23:502-511. 2006
  • Deposition of mouse amyloid β in human APP/PS1 double and single AD model transgenic mice.  23:653-662. 2006
  • Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein.  20:656-665. 2005
  • Red cell interactions with amyloid-β1-40 fibrils in a murine model.  19:28-37. 2005
  • Erratum: Gender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice (Neurobiology of Disease (2003) 14 (318-327) DOI: 10.1016/j.nbd.2003.08.009).  16:290. 2004
  • Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: Analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation.  14:624-636. 2003
  • DNA microarray analysis of functionally discrete human brain regions reveals divergent transcriptional profiles.  14:240-250. 2003
  • Gender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice.  14:318-327. 2003
  • TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion.  12:11-24. 2003
  • Cellular distribution of NMDA glutamate receptor subunit mRNAs in the human cerebellum.  4:35-46. 1997
  • Huntington’s disease cag trinucleotide repeats in pathologically confirmed post-mortem brains.  1:159-166. 1994
  • International Standard Serial Number (issn)

  • 0969-9961
  • Electronic International Standard Serial Number (eissn)

  • 1095-953X